Department of Cardiology, Institute of Cardiovascular Diseases, First Affiliated Hospital of Dalian Medical University, Dalian, China.
School of Public Health, Dalian Medical University, Dalian, China.
Life Sci. 2018 Aug 15;207:304-313. doi: 10.1016/j.lfs.2018.06.018. Epub 2018 Jun 27.
Atherosclerosis (AS), a chronic arterial disease, is one of the major causes of morbidity and mortality worldwide. Several treatment modalities have been demonstrated to be effective in treating AS; however, the mortality rate due to AS remains high. Sonodynamic therapy (SDT) is a promising new treatment using low-intensity ultrasound in combination with sonosensitizers. Although SDT was developed from photodynamic therapy (PDT), it has a stronger tissue-penetrating capability and exhibits a more focused effect on the target lesional site requiring treatment. Furthermore, SDT has been demonstrated to suppress the formation of atheromatous plaques, and it can increase plaque stability both in vitro and in vivo. In this article, we critically summarize the recent literature on SDT, focusing on its possible mechanism of action as well as the existing and newly discovered sonosensitizers and chemotherapeutic agents for the treatment of AS.
动脉粥样硬化（AS）是一种慢性动脉疾病，是全球发病率和死亡率的主要原因之一。已经有几种治疗方式被证明对 AS 有效，但是由于 AS 导致的死亡率仍然很高。声动力学疗法（SDT）是一种有前途的新治疗方法，使用低强度超声联合声敏剂。尽管 SDT 是从光动力学疗法（PDT）发展而来，但它具有更强的组织穿透能力，并对需要治疗的靶病变部位表现出更集中的作用。此外，SDT 已被证明可抑制动脉粥样硬化斑块的形成，并且可以在体外和体内增加斑块的稳定性。在本文中，我们批判性地总结了 SDT 的最新文献，重点介绍了其可能的作用机制以及现有的和新发现的用于治疗 AS 的声敏剂和化疗药物。
